Cancer Biological Therapy Market size worth $100bn by 2023 (1)

1
Cancer Biological Therapy Market size worth
100bn by 2023
2
Cancer Biological Therapy Market size worth
100bn by 2023

• Cancer Biological Therapy Market size was USD
  61.3 billion in 2015, with revenue forecast to
  cross USD 100 billion, at upwards of 6 growth
  from 2016 to 2023.
• Rise in incidence rate of various cancers and
  growing adoption of biological therapy will drive
  the growth of the global cancer biological
  therapy market.
• According to WHO, the number of new cancer cases
  is projected to rise 70 in the coming two
  decades, mainly due to increased use of tobacco
  and alcohol consumption. 
• As per NCI, an estimated 16,85,210 new cases will
  be diagnosed in 2016, and about 5,95,690
  individuals will succumb to the disease in the
  U.S.
• Growing global geriatric population is predicted
  to boost biological cancer therapy market size
  owing to link between new cases and old age.
  Elderly population is more prone to the disease,
  and as per the ACS, 86 of cases in the U.S. were
  recorded in individuals aged 50 and above.
• https//www.gminsights.com/industry-analysis/cance
  r-biological-therapy-market

3
Continue.....

• This is due to accumulation of mutations in aged
  individuals body over time coupled with a
  reduction in the DNA mismatch repair process in
  hematopoietic stem cells (HSC).
• The high treatment cost of oncology therapy is
  primarily due to high cost of drug development.
  Millions of dollars are spent in identifying or
  designing a drug, obtaining preclinical data and
  clinical trials.
• It is estimated that each drug costs about USD
  1.2 to USD 1.3 billion.
• Monopoly is another factor contributing to high
  costs.
• There are very few companies engaged in the
  manufacture of drugs resulting in reduced
  competition and higher prices, which restrains
  the global cancer biologic therapy market.
• Cancer vaccines market was over USD 1.9 billion
  in 2015. Approval of the first vaccine
  sipuleucel-T (Provenge) for metastatic prostate
  cancer by the FDA will boost growth in the
  immunotherapy segment.
• Get more detail _at_ https//www.gminsights.com/indus
  try-analysis/cancer-biological-therapy-market

4
U.S. Cancer Biological Therapy Market size, by
product, 2012 - 2023 (USD Million)

https//www.gminsights.com/request-sample/detail/6
76
5
360 Analysis

• Product Analysis
• Monoclonal antibodies market size was over USD 21
  billion in 2015. Antibody therapy is the most
  successful and important approach for treatment
  of hematological malignance and  solid tumors.
  Bispecific monoclonal antibodies are anticipated
  to grow at  6.5 CAGR from 2016 to 2023.
• Regional Analysis
• Increased public funding for RD and other
  government initiatives is expected to drive
  growth in North America over the forecast period.
  Germany cancer biological therapy market size was
  over USD 4.3 billion in 2015. It is expected to
  continue revenue share dominance due to increased
  prevalence and favorable public reimbursement and
  insurance policies.
• Competitive Market Share
• Novartis International Ag, Amgen Inc., Merck
  Co., Inc., Bristol-Myers Squibb, GlaxoSmithKline
  Plc, F. Hoffmann-La Roche AG, Eli Lilly, Seattle
  Genetics, Inc., Spectrum Pharmaceuticals, Inc.,
  Celgene Corporation are some notable companies
  vying for global cancer biological therapy market
  share.
• Get more detail _at_ https//www.gminsights.com/indus
  try-analysis/cancer-biological-therapy-market

6

Latest Research Report On Cancer Biological
Therapy Market _at_ https//www.gminsights.com/indust
ry-analysis/cancer-biological-therapy-market
Download Latest Report PDF _at_ https//www.gminsig
hts.com/request-sample/detail/676
7
Stay In Touch You can visit us at
www.gminsights.com